Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

Breast cancer deaths among women ages 20-49 declined significantly between 2010 and 2020, according to a new study.

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

While breast cancer incidence increased between 2018 and 2022, mortality rates for women ages 20 to 49 declined significantly between 2010 and 2020, according to new research presented April 29 at the ...

Select patients with breast cancer who experience pathologic complete response to neoadjuvant systemic therapy and undergo ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzbekistan.

The Incucyte ® Live-Cell Analysis System is a fully automated platform for phase contrast and two-color fluorescence imaging, ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.